Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2003 Oct;22(10):597-602.
doi: 10.1007/s10096-003-0998-z. Epub 2003 Sep 24.

Risk factors for development of paradoxical response during antituberculosis therapy in HIV-negative patients

Affiliations
Comparative Study

Risk factors for development of paradoxical response during antituberculosis therapy in HIV-negative patients

V C C Cheng et al. Eur J Clin Microbiol Infect Dis. 2003 Oct.

Abstract

The risk factors for development of paradoxical response were studied in a cohort of 104 patients with culture-documented Mycobacterium tuberculosis infection. Paradoxical deterioration occurred in 16 (15.4%) patients (case group) during antituberculosis therapy, involving lungs and pleura (n=4), spine and paraspinal tissue (n=5), intracranium (n=3), peritoneum (n=2), bone and joint (n=1), and lymph node (n=1). The median time from commencement of treatment to paradoxical deterioration was 56 days (range, 20-109 days). Compared with 53 patients without clinical deterioration after antituberculosis therapy (control group), patients with paradoxical response were more likely to have extrapulmonary involvement (62.5% vs. 17.0%; P<0.05) at initial diagnosis, to have lower baseline lymphocyte counts (672+/-315 cells/microl vs. 1,328+/-467 cells/microl; P<0.001), and to exhibit a greater surge in lymphocyte counts (627+/-465 cells/microl vs. 225+/-216 cells/microl; P<0.05) during paradoxical response. Further studies on lymphocyte subsets and cytokine levels would be useful in understanding the exact immunological mechanisms involved in immunorestitution.

PubMed Disclaimer

References

    1. Eur J Clin Microbiol Infect Dis. 2001 Jun;20(6):402-6 - PubMed
    1. Chest. 1998 Sep;114(3):933-6 - PubMed
    1. Int J Tuberc Lung Dis. 2001 Apr;5(4):370-5 - PubMed
    1. J Clin Microbiol. 2000 Sep;38(9):3194-9 - PubMed
    1. Am J Respir Crit Care Med. 1997 Jun;155(6):2057-63 - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources